The Goldman Sachs Group, Inc. 13D and 13G filings for 4D Molecular Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-02-09 4:05 pm Sale | 2025-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 4,286,077 7.500% | -137,358 (-3.11%) | Filing |
| 2025-02-10 5:28 pm Purchase | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | GOLDMAN SACHS GROUP INC GS | 4,423,435 9.600% | 4,423,435 (New Position) | Filing |